[1]
|
Rashid, M., Toh, T.B., Hooi, L., et al. (2018) Optimizing Drug Combinations against Multiple Myeloma Using a Quad-ratic Phenotypic Optimization Platform (QPOP). Science Translational Medicine, 10, eaan0941.
https://doi.org/10.1126/scitranslmed.aan0941
|
[2]
|
刘婷婷, 侯健. 高危多发性骨髓瘤的现状挑战与思考[J]. 中国肿瘤临床, 2021, 48(6): 271-274.
|
[3]
|
管鑫鑫, 刘松江. 多发性骨髓瘤的研究进展[J]. 临床医学进展, 2022, 12(11): 10138-10145.
https://doi.org/10.12677/acm.2022.12111462
|
[4]
|
刘志强, 夏海龙, 李承君, 夏磊. 硼替佐米不同给药途径对周围神经病变的发生率和风险的影响[J]. 中国实验血液学杂志, 2019, 27(5): 1654-1663.
|
[5]
|
Delforge, M., Bladé, J., Dimopoulos, M.A., et al. (2010) Treatment-Related Peripheral Neuropathy in Multiple Myeloma: The Challenge Con-tinues. The Lancet Oncology, 11, 1086-1095.
https://doi.org/10.1016/S1470-2045(10)70068-1
|
[6]
|
董世武, 胡文辉. 破而后立: 骨骼系统中破骨细胞新功能解析[J]. 第三军医大学学报, 2022, 44(1): 79-88.
|
[7]
|
蔡宜诺, 刘景华, 张美玉, 等. 多发性骨髓瘤中枢神经系统浸润7例临床分析[J]. 重庆医学, 2021, 50(2): 220-223.
|
[8]
|
董会卿. 神经副肿瘤综合征[J]. 中国神经免疫学和神经病学杂志, 2020, 27(2): 96-99.
|
[9]
|
Morawska, M., Grzasko, N., Kostyra, M., et al. (2015) Therapy-Related Pe-ripheral Neuropathy in Multiple Myeloma Patients. Hematological Oncology, 33, 113-119. https://doi.org/10.1002/hon.2149
|
[10]
|
Dimopoulos, M.A., Mateos, M.V., Richardson, P.G., et al. (2011) Risk Factors for, and Reversibility of, Peripheral Neuropathy Associated with Bortezomib-Melphalan-Prednisone in Newly Diagnosed Patients with Multiple Myeloma: Sub-Analysis of the Phase 3 VISTA Study. European Journal of Haema-tology, 86, 23-31.
https://doi.org/10.1111/j.1600-0609.2010.01533.x
|
[11]
|
Richardson, P.G., Sonneveld, P., Schuster, M.W., et al. (2009) Reversibility of Symptomatic Peripheral Neuropathy with Bortezomib in the Phase III APEX Trial in Relapsed Multiple Myeloma: Impact of a Dose-Modification Guideline. British Journal of Haematology, 144, 895-903. https://doi.org/10.1111/j.1365-2141.2008.07573.x
|
[12]
|
Hrusovsky, I., Emmerich, B., Von Rohr, A., et al. (2011) Bortezomib Retreatment in Relapsed Multiple Myeloma—Results from a Retrospective Multicentre Survey in Germany and Switzerland. Oncology, 79, 247-254.
https://doi.org/10.1159/000322866
|
[13]
|
Petrucci, M.T., Giraldo, P., Corradini, P., et al. (2013) A Prospective, In-ternational Phase 2 Study of Bortezomib Retreatment in Patients with Relapsed Multiple Myeloma. British Journal of Haematology, 160, 649-659.
https://doi.org/10.1111/bjh.12198
|
[14]
|
Richardson, P.G., et al. (2009) Single-Agent Bortezomib in Previously Un-treated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations with Re-sponse and Neuropathy. Journal of Clinical Oncology, 27, 3518-3525. https://doi.org/10.1200/JCO.2008.18.3087
|
[15]
|
Richardson, P.G., Delforge, M., Beksaç, M., et al. (2012) Man-agement of Treatment-Emergent Peripheral Neuropathy in Multiple Myeloma. Leukemia, 26, 595-608. https://doi.org/10.1038/leu.2011.346
|
[16]
|
Mileshkin, L., Stark, R., Day, B., et al. (2006) Development of Neurop-athy in Patients with Myeloma Treated with Thalidomide: Patterns of Occurrence and the Role of Electrophysiologic Monitoring. Journal of Clinical Oncology, 24, 4507-4514. https://doi.org/10.1200/JCO.2006.05.6689
|
[17]
|
Koeppen, S. (2014) Treatment of Multiple Myeloma: Thalidomide-, Bortezomib-, and Lenalidomide-Induced Peripheral Neuropathy. Oncology Research and Treatment, 37, 506-513. https://doi.org/10.1159/000365534
|
[18]
|
姚卫芹, 颜灵芝, 商京晶, 等. 来那度胺联合硼替佐米和地塞米松诱导治疗初诊多发性骨髓瘤患者的疗效和安全性[J]. 中华血液学杂志, 2022, 43(8): 657.
|
[19]
|
李校堃, 刘旭, 刘建华, 等. 细胞生长因子在神经康复与神经可塑性中的研究进展[J]. 中国康复理论与实践, 2022, 28(2): 175-182.
|
[20]
|
杨便红, 南虹, 刘爽, 等. 循证护理模式对多发性骨髓瘤不良反应干预调查及实践研究[J]. 护理学, 2022, 11(4): 484.
|
[21]
|
多发性骨髓瘤中西医结合诊疗专家共识(2019) [J]. 中华医学杂志, 2019(28): 2169-2175.
|
[22]
|
孙章艳, 肖天宝. 黄芪桂枝五物汤对化疗后周围神经病变临床及机制的研究进展[J]. 世界最新医学信息文摘, 2017, 17(24): 23-25, 27.
|
[23]
|
何小刚, 等. 从脾肾阳虚论治痿证[J]. 中医药学报, 2014, 42(3): 129-130.
|
[24]
|
曹鹏, 霍介格. 从血携论治化疗相关性周围神经病变[J]. 光明中医, 2013, 28(1): 12-13.
|
[25]
|
杨薛, 胡致平. 论痰在多发性骨髓瘤中医病因病机中的作用[J]. 浙江中医药大学学报, 2018, 42(7): 547-549.
|
[26]
|
杨小芳, 阮莉娅, 程秋琴. 五味消毒饮加味预防VAD方案治疗多发性骨髓瘤致周围神经病变35例[J]. 浙江中医杂志, 2022, 57(3): 205-206.
|
[27]
|
崔思远, 杨真, 崔兴, 等. 补肾活血通络方联合改良PD方案诱导治疗初治多发性骨髓瘤疗效观察[J]. 辽宁中医杂志, 2019(5): 987-990.
|
[28]
|
陈银崧, 吴静文, 莫美娟. 温经活络外治法治疗多发性骨髓瘤合并早期周围神经病变临床研究[J]. 河南中医, 2022, 42(6): 919-922.
|
[29]
|
郭玲, 李倩, 曹灿, 彭艳, 雷娟娟, 江劲波. 中药熏洗法治疗多发性骨髓瘤周围神经病变临床研究[J]. 中医药临床杂志, 2021, 33(3): 536-539.
|
[30]
|
王骁, 陈丽, 刘广杰, 等. 骨转移癌疼痛的治疗进展[J]. 中国全科医学, 2020, 23(12): 1571.
|
[31]
|
Liu, J.H., Fan, H.S., Deng, S.H., et al. (2021) Central Nervous System Toxicity Caused by Bortezomib: Five Case Reports and a Review of Literature. Chinese Journal of Hematology, 42, 63-69.
|
[32]
|
王磊, 徐晓度, 姚利娟, 黄雨婷, 邹璆, 吴冰, 殷德猛. 针灸对多发性骨髓瘤患者化疗相关周围神经病变的干预效果[J]. 实用临床医药杂志, 2022, 26(2): 28-30.
|
[33]
|
赵薇薇, 董秀帅, 刘瑶, 等. 硼替佐米治疗多发性骨髓瘤致消化系统自主神经病变相关研究[J]. 临床血液学杂志, 2022, 35(7): 486-489.
|
[34]
|
田艳萍, 张莹, 贾英杰. 温针灸对奥沙利铂化疗后外周神经毒性的疗效观察[J]. 天津中医药, 2011, 28(3): 212-213.
|